Respiratory Syncytial Virus - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for respiratory syncytial virus including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for respiratory syncytial virus

Respiratory syncytial virus (RSV) is one of the most common diseases that affect children. RSV is one of the human pathogens in infants, young children, and the elderly. It also affects people with an impaired immune system. Almost all children are exposed to respiratory syncytial virus by the age of two. RSV causes common cold symptoms in most patients. In unguarded children, RSV can develop into either bronchiolitis or pneumonia or even both with increased chances of notable morbidity or death. The common symptoms of respiratory syncytial virus are common cold, sore throat, stuffy and runny nose, fever, and inflammation in the airways of the lungs. A person infected with RSV is highly contagious, as the respiratory syncytial virus enters the body through eyes, nose, or mouth. The most efficient approach for the treatment of respiratory syncytial virus is emerging to be monotherapy. 

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for respiratory syncytial virus. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of respiratory syncytial virus. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Ablynx
• Agilvax
• AlphaVax

Therapeutic assessment of the drug development pipeline for respiratory syncytial virus by route of administration

• Oral
• Intramuscular
• Inhalation
• Intravenous
• Unknown

The oral route of administration (ROA) involves the delivery of the drug directly into the mouth cavity and in the intramuscular technique, the molecules are administered directly into the muscle, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for respiratory syncytial virus by therapy

• Monotherapy
• Combination therapy
• Unknown

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for respiratory syncytial virus are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for respiratory syncytial virus?
• What are the companies that are currently involved in the development of drug development molecules for respiratory syncytial virus?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.